TY - JOUR T1 - Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 3741 LP - 3746 VL - 36 IS - 7 AU - YOICHIRO YOSHIDA AU - MASAYASU NAITO AU - TEPPEI YAMADA AU - NAOYA AISU AU - KOJIMA DAIBO AU - TOSHIYUKI MERA AU - TOSHIHIRO TANAKA AU - KEIKO NAITO AU - KOSEI YASUMOTO AU - TAKASHI KAMIGAKI AU - SHIGENORI GOTO AU - YUICHI YAMASHITA AU - SUGURU HASEGAWA Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3741.abstract N2 - Background/Aim: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC). Patients and Methods: Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy. Results: Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal. Conclusion: Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe. ER -